Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Mier

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Experimental Medicine|November 1, 1993
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cellsH Tilg, E Vannier, G Vachino, et al.
Journal of Clinical & Laboratory Immunology|April 1, 1990
Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapyR W Bergstrom, M B Atkins, J W Mier, et al.
The Journal of Biological Chemistry|January 9, 2001
Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cellsD J Panka, T Mano, T Suhara, et al.
Cellular Immunology|October 1, 1990
Pro-interleukin-1 beta production by a subpopulation of human T cells, but not NK cells, in response to interleukin-2R P Numerof, A N Kotik, C A Dinarello, et al.
Chest|March 1, 1992
Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parametersP J Vogelzang, S M Bloom, J W Mier, et al.
Blood|January 1, 1994
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55H Tilg, E Trehu, M B Atkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1993
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimeraH Tilg, L Shapiro, M B Atkins, et al.
The Journal of Biological Chemistry|November 21, 1998
Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independentR A Janssen, K G Veenstra, P Jonasch, et al.
The Journal of Experimental Medicine|November 1, 1981
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factorJ E Gootenberg, F W Ruscetti, J W Mier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1989
Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapyJ W Mier, E P Brandon, P Libby, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Experimental Medicine|November 1, 1993
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cellsH Tilg, E Vannier, G Vachino, et al.
Journal of Clinical & Laboratory Immunology|April 1, 1990
Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapyR W Bergstrom, M B Atkins, J W Mier, et al.
The Journal of Biological Chemistry|January 9, 2001
Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cellsD J Panka, T Mano, T Suhara, et al.
Cellular Immunology|October 1, 1990
Pro-interleukin-1 beta production by a subpopulation of human T cells, but not NK cells, in response to interleukin-2R P Numerof, A N Kotik, C A Dinarello, et al.
Chest|March 1, 1992
Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parametersP J Vogelzang, S M Bloom, J W Mier, et al.
Blood|January 1, 1994
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55H Tilg, E Trehu, M B Atkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1993
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimeraH Tilg, L Shapiro, M B Atkins, et al.
The Journal of Biological Chemistry|November 21, 1998
Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independentR A Janssen, K G Veenstra, P Jonasch, et al.
The Journal of Experimental Medicine|November 1, 1981
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factorJ E Gootenberg, F W Ruscetti, J W Mier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1989
Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapyJ W Mier, E P Brandon, P Libby, et al.
Pageof 9